Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Jul 28;4(2):261-266.
doi: 10.1159/000318742.

Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention

Shogo Ohkoshi  1 , Satoshi Yamagiwa, Masahiko Yano, Hiromichi Takahashi, Yo-Hei Aoki, Yasunobu Matsuda, Yutaka Aoyagi
Affiliations
Case Reports

Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention

Shogo Ohkoshi et al. Case Rep Gastroenterol. .

Abstract

Despite the recent progress in interferon (IFN) therapies for chronic hepatitis C, liver cirrhosis remains refractory. One of the major obstacles to successful IFN therapy is low platelet count. Currently, splenic interventions, such as partial splenic embolization (PSE) or surgical splenectomy, have been applied effectively and make standard IFN therapy possible. However, there may be a group of patients with low platelet counts who can be treated without splenic intervention. We here report two patients with advanced type C liver cirrhosis who were successfully treated using very-low-dose pegylated interferon a2a plus ribavirin. One patient had a very low platelet count (2.5 x 10(4)/mul) due to splenomegaly before treatment. However, pretreatment serum HCV titers were low in both patients and early viral responses were obtained in both. Because PSE or splenectomy may still have some safety concerns, this attenuated IFN treatment protocol can be an alternative therapeutic option for patients with advanced type C liver disease, but good virological factors for sustained virological response.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes in laboratory data (ALT, WBC, platelets) for patients 1 and 2 after the start of PEG-IFNa2a. The vertical axis shows the values for ALT and WBC (left) and platelets (right).
See this image and copyright information in PMC

References

    1. NIH Consensus Statement on Management of Hepatitis C 2002 NIH Consens State Sci Statements. 2002;19:1–46. - PubMed
    1. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17–27. - PubMed
    1. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol. 2008;5:610–622. - PubMed
    1. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat. 2007;14(suppl 1):82–88. - PubMed
    1. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675–1684. - PubMed

Publication types